Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07816692) titled 'iDose TR Administration in an Office-Based Surgery Setting' on Sept. 8.

Study Type: Observational

Primary Sponsor: Glaukos Corporation

Condition: Open Angle Glaucoma (OAG) Ocular Hypertension (OHT)

Intervention: Combination Product: iDose TR (travoprost intracameral implant) 75 µg

Recruitment Status: Recruiting

Date of First Enrollment: May 13, 2026

Target Sample Size: 30

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07816692

Published by HT Digital Content Services with permission from Health Daily Digest....